Home › Research › Cognitive tests and assessment
GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study
Szwedo AA, Dalen I, Pedersen KF, Camacho M, Bäckström D, Forsgren L, Tzoulis C, Winder-Rhodes S et al.. Movement disorders : official journal of the Movement Disorder Society, 2022-02-02
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Common genetic variance in apolipoprotein E (APOE), β-glucocerebrosidase (GBA), microtubule-associated protein tau (MAPT), and α-synuclein (SNCA) has been linked to cognitive decline in Parkinson's disease (PD), although studies have yielded mixed results. Objectives To evaluate the effect of genetic variants in APOE, GBA, MAPT, and SNCA on cognitive decline and risk of dementia in a pooled analysis of six longitudinal, non-selective, population-based cohorts of newly diagnosed PD patients. Methods 1002 PD patients, followed for up to 10 years (median 7.2 years), were genotyped for at least one of APOE-ε4, GBA mutations, MAPT H1/H2, or SNCA rs356219.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 281 participants. This pooled analysis of six population-based cohorts genotyped 1002 patients with newly diagnosed Parkinson's disease for APOE, GBA, MAPT, and SNCA variants and followed them for up to 10 years to assess cognitive decline and dementia risk. Reported effect size: 29.7%; 10.3%; HR 3.57.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Szwedo, A. A., Dalen, I., Pedersen, K. F., Camacho, M., Bäckström, D., Forsgren, L., et al. (2022). GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study. Movement disorders : official journal of the Movement Disorder Society. https://doi.org/10.1002/mds.28932
Vancouver
Szwedo AA, Dalen I, Pedersen KF, Camacho M, Bäckström D, Forsgren L, et al. GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study. Movement disorders : official journal of the Movement Disorder Society. 2022. doi:10.1002/mds.28932. PMID: 35106798.
BibTeX
@article{szwedo2022-35106798,
author = {Szwedo, A. A. and Dalen, I. and Pedersen, K. F. and Camacho, M. and Bäckström, D. and Forsgren, L. and Tzoulis, C. and Winder-Rhodes, S. and others},
title = {{GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study}},
journal = {Movement disorders : official journal of the Movement Disorder Society},
year = {2022},
doi = {10.1002/mds.28932},
pmid = {35106798},
url = {https://doi.org/10.1002/mds.28932}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Objectives To evaluate the effect of genetic variants in APOE, GBA, MAPT, and SNCA on cognitive decline and risk of dementia in a pooled analysis of six longitudinal, non-selective, population-based cohorts of newly diagnosed PD patients.
- Methods 1002 PD patients, followed for up to 10 years (median 7.2 years), were genotyped for at least one of APOE-ε4, GBA mutations, MAPT H1/H2, or SNCA rs356219.
- We evaluated the effect of genotype on the rate of cognitive decline (Mini-Mental State Examanation, MMSE) using linear mixed models and the development of dementia (diagnosed using standardized criteria) using Cox regression; multiple comparisons were accounted for using Benjamini-Hochberg corrections.
- Results Carriers of APOE-ε4 (n = 281, 29.7%) and GBA mutations (n = 100, 10.3%) had faster cognitive decline and were at higher risk of progression to dementia (APOE-ε4, HR 3.57, P < 0.001; GBA mutations, HR 1.76, P = 0.001) than non-carriers.
Why it matters
This pooled analysis of six population-based cohorts genotyped 1002 patients with newly diagnosed Parkinson's disease for APOE, GBA, MAPT, and SNCA variants and followed them for up to 10 years to assess cognitive decline and dementia risk. It examines genetic influences on cognitive decline in Parkinson's disease and does not test any treatment, cure, or prevention.
Study details
- Study designlongitudinal study
- Participants281
- Effect size29.7%; 10.3%; HR 3.57
- Evidence strengthModerate
How this study scored 70/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Movement disorders : official journal of the Movement Disorder Society) |
| Journal's citation record | 3 / 4 | Movement Disorders: journal h-index 281 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 2 / 4 | 281 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 118 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 19.7 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 4 / 6 | Cited 11.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 3 / 4 | Cited 74 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Jodi Maple‐Grødem: h-index 31 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 13 institution(s) in 5 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35106798) |
| Free to read | 2 / 2 | Free to read |
| Total | 70 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 19.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in Cognitive tests and assessment from nearby years
Also tagged “lewy”
1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.